<DOC>
	<DOC>NCT03098589</DOC>
	<brief_summary>To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)). 1. Planned registration period 3 years 2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL</brief_summary>
	<brief_title>Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
	<mesh_term>Leukemia, T-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Relapsed or Refractory Adult Tcell Leukemia Lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adult T-cell Leukemia Lymphoma</keyword>
	<keyword>Teratogenicity</keyword>
	<keyword>Myelosuppression</keyword>
	<keyword>Haemorrhage</keyword>
	<keyword>Infection</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Tumor lysis syndrome</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Ischaemic heart disease</keyword>
	<keyword>Cardiac failure</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Hepatic disorder</keyword>
	<keyword>Hypothyroidism</keyword>
	<keyword>Gastrointestinal perforation</keyword>
	<keyword>Orthostatic hypotension</keyword>
	<keyword>Convulsion</keyword>
	<keyword>Somnolence</keyword>
	<keyword>Confusion</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Dizziness</keyword>
	<keyword>Blurred vision</keyword>
	<keyword>Second primary cancer</keyword>
	<keyword>Cataract</keyword>
	<keyword>Revlimid capsules</keyword>
</DOC>